Bolt Biotherapeutics, Inc. cash flow to debt ratio of -173.58% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Bolt Biotherapeutics, Inc.'s free cash flow has increased -34.91% from $-61.33M last year to $-39.92M, signaling increasing performance

Bolt Biotherapeutics, Inc.'s debt to equity ratio is 1.13, which means that the company's assets are unhealthy financed, signaling financial risk.

Bolt Biotherapeutics, Inc.'s debt has increased relative to shareholder equity from 0.44 last year to 1.13 today, signaling weakened financials

Bolt Biotherapeutics, Inc. has a net cash position, so leverage is healthy.

Bolt Biotherapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Bolt Biotherapeutics, Inc.'s profit margin has increased (-44.55%) in the last year from -820.78% to -455.15%, signaling increasing performance

Bolt Biotherapeutics, Inc.'s short-term assets of $30.26M exceed its short-term liabilities of $8.44M

Bolt Biotherapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Bolt Biotherapeutics, Inc.'s return on equity of -100.90%, is lower than 15.00%, indicating bad performance

Bolt Biotherapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Bolt Biotherapeutics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Bolt Biotherapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Bolt Biotherapeutics, Inc. has negative free cash flow, indicating cash burn

Bolt Biotherapeutics, Inc.'s yearly earnings has increased -47.12% since last year from $-63.12M to $-33.38M, signaling increasing performance

Bolt Biotherapeutics, Inc.'s yearly revenue has increased 0.07% since last year from $7.69M to $7.70M, signaling increasing performance

ROIC -69.02% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Bolt Biotherapeutics, Inc.'s 3-year revenue CAGR of 10.33% is positive, indicating growing revenue over the past 3 years

Bolt Biotherapeutics, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Bolt Biotherapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Bolt Biotherapeutics, Inc. has insufficient data to evaluate this check.

Bolt Biotherapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Bolt Biotherapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Bolt Biotherapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Bolt Biotherapeutics, Inc. has insufficient data to evaluate this check.

Bolt Biotherapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Bolt Biotherapeutics, Inc. has a price-to-book ratio of 0.38x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Bolt Biotherapeutics, Inc. has a price-to-sales ratio of 1.15x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue